Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Beraprost Sodium Tablets (Dorner) and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients

NCT02786979 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02786979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02786979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Beraprost Sodium Tablets (Dorner) and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Terminated
Start date
July 31, 2010
Completion date
January 31, 2013
Enrollment
190 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus